(Reuters) Merck said on Tuesday it was planning to produce and donate investigational Sudan ebolavirus vaccine to a global non-profit organization’s research program in Uganda, which is facing an outbreak of the disease. The investigational vaccine that will be donated to IAVI is similar to Merck’s Ervebo vaccine, which is approved against the Zaire ebolavirus strain.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.